Update on the treatment of psoriasis and psoriatic arthritis – role of apremilast

References

• KurdSKGelfandJMThe prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003–2004J Am Acad Dermatol200960221822419022533
   PubMed Web of Science ®Google Scholar
• ParisiRSymmonsDPGriffithsCEAshcroftDMIdentification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project teamGlobal epidemiology of psoriasis: a systematic review of incidence and prevalenceJ Invest Dermatol2013133237738523014338
   PubMed Web of Science ®Google Scholar
• GladmanDDPsoriatic arthritis from Wright’s era until todayJ Rheumatol Suppl2009834819661526
   PubMedGoogle Scholar
• ReichKKrügerKMössnerRAugustinMEpidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasisBr J Dermatol200916051040104719210498
   PubMed Web of Science ®Google Scholar
• BoehnckeWHSchönMPPsoriasisLancet Epub2015526
   PubMed Web of Science ®Google Scholar
• GhoreschiKWeigertCRöckenMImmunopathogenesis and role of T cells in psoriasisClin Dermatol200725657458018021895
   PubMed Web of Science ®Google Scholar
• GhoreschiKLaurenceAYangXHiraharaKO’SheaJJT helper 17 cell heterogeneity and pathogenicity in autoimmune diseaseTrends Immunol201132939540121782512
   PubMed Web of Science ®Google Scholar
• GhoreschiKLaurenceAYangXGeneration of pathogenic T(H)17 cells in the absence of TGF-b signallingNature2010467731896797120962846
   PubMed Web of Science ®Google Scholar
• BelgeKBrückJGhoreschiKAdvances in treating psoriasisF1000Prime Rep20146424592316
   PubMedGoogle Scholar
• BaliwagJBarnesDHJohnstonACytokines in psoriasisCytokine201573234235025585875
   PubMed Web of Science ®Google Scholar
• NestleFOKaplanDHBarkerJPsoriasisN Engl J Med2009361549650919641206
   PubMed Web of Science ®Google Scholar
• LeipeJGrunkeMDechantCRole of Th17 cells in human autoimmune arthritisArthritis Rheum201062102876288520583102
   PubMed Web of Science ®Google Scholar
• GladmanDDClinical aspects of the spondyloarthropathiesAm J Med Sci199831642342389766484
   PubMed Web of Science ®Google Scholar
• HustedJAGladmanDDFarewellVTCookRJHealth-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritisArthritis Rheum200145215115811324779
   PubMed Web of Science ®Google Scholar
• HustedJATomBDFarewellVTSchentagCTGladmanDDA longitudinal study of the effect of disease activity and clinical damage on physical function over the course of psoriatic arthritis: Does the effect change over time?Arthritis Rheum200756384084917328058
   PubMed Web of Science ®Google Scholar
• GladmanDDShuckettRRussellMLThorneJCSchachterRKPsoriatic arthritis (PSA) – an analysis of 220 patientsQ J Med1987622381271413659255
   PubMedGoogle Scholar
• HuynhDKavanaughAPsoriatic arthritis: current therapy and future approachesRheumatology (Oxford)2015541202825125588
   PubMed Web of Science ®Google Scholar
• GossecLSmolenJSGaujoux-VialaCEuropean League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. European League Against RheumatismAnn Rheum Dis201271141221953336
   PubMed Web of Science ®Google Scholar
• GhoreschiKGadinaMJakpot! New small molecules in autoimmune and inflammatory diseasesExp Dermatol2014231711
   PubMed Web of Science ®Google Scholar
• SchaferPHPartonAGandhiAKApremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasisBr J Pharmacol2010159484285520050849
   PubMed Web of Science ®Google Scholar
• de Waal MalefytRAbramsJBennettBFigdorCGde VriesJEInterleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytesJ Exp Med19911745120912201940799
   PubMed Web of Science ®Google Scholar
• TilgHTrehuEAtkinsMBDinarelloCAMierJWInterleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55Blood19948311131188274730
   PubMed Web of Science ®Google Scholar
• SerezaniCHBallingerMNAronoffDMPeters-GoldenMCyclic AMP: master regulator of innate immune cell functionAm J Respir Cell Mol Biol200839212713218323530
   PubMed Web of Science ®Google Scholar
• ZambonACZhangLMinovitskySGene expression patterns define key transcriptional events in cell-cycle regulation by cAMP and protein kinase AProc Natl Acad Sci U S A2005102248561856615939874
   PubMed Web of Science ®Google Scholar
• OllivierVParryGCCobbRRde ProstDMackmanNElevated cyclic AMP inhibits NF-kappaB-mediated transcription in human monocytic cells and endothelial cellsJ Biol Chem19962713420828208358702838
   PubMed Web of Science ®Google Scholar
• FrancisSHBlountMACorbinJDMammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functionsPhysiol Rev201191265169021527734
   PubMed Web of Science ®Google Scholar
• HouslayMDSchaferPZhangKYKeynote review: phosphodiesterase-4 as a therapeutic targetDrug Discov Today200510221503151916257373
   PubMed Web of Science ®Google Scholar
• SchaferPHPartonACaponeLApremilast is a selective PDE4 inhibitor with regulatory effects on innate immunityCell Signal20142692016202924882690
   PubMed Web of Science ®Google Scholar
• MolostvovGMorrisARosePBasuSMullerGThe effects of selective cytokine inhibitory drugs (CC-10004 and CC-1088) on VEGF and IL-6 expression and apoptosis in myeloma and endothelial cell co-culturesBr J Haematol2004124336637514717786
   PubMed Web of Science ®Google Scholar
• ItoTAndoHSuzukiTIdentification of a primary target of thalidomide teratogenicityScience201032759711345135020223979
   PubMed Web of Science ®Google Scholar
• McCannFEPalfreemanACAndrewsMApremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritisArthritis Res Ther2010123R10720525198
   PubMed Web of Science ®Google Scholar
• KavanaughAMeasePJGomez-ReinoJJTreatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitorAnn Rheum Dis20147361020102624595547
   PubMed Web of Science ®Google Scholar
• Otezla^® (apremilast) tablets for oral use [prescribing information]Summit, NJCelgene Corporation2014 Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003746/WC500182627.pdfAccessed August 26, 2015
   Google Scholar
• Celgene.com [homepage on the Internet]Positive Results from Phase III Study Evaluating Oral OTEZLA® (Apremilast) or Injectable Etanercept versus Placebo in Patients with Moderate to Severe Plaque Psoriasis Presented at AADCelgene Corporation2015 [updated Mar 20, 2015; cited May 17, 2015]. Available from: http://ir.celgene.com/releasedetail.cfm?releaseid=902701Accessed May 17, 2015
   Google Scholar
• CutoloMMyersonGEFleischmannRMLong-Term (52-Week) Results Of a Phase 3, Randomized, Controlled Trial Of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, In Patients With Psoriatic Arthritis (PALACE 2). [abstract]Arthritis Rheum201365Suppl 1081523280587
   PubMed Web of Science ®Google Scholar
• EdwardsCJBlancoFJCrowleyJLong-term 52-week results of PALACE 3, a Phase III, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement [abstract 212]Rheumatology201453Suppl 1i138
   PubMed Web of Science ®Google Scholar
• KavanaughAMeasePJGomez-ReinoJJLongterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritisJ Rheumatol201542347948825593233
   PubMed Web of Science ®Google Scholar
• MeasePJGladmanDDKavanaughALong-Term Safety and Tolerability Of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, In Patients With Psoriatic Arthritis: Pooled Safety Analysis Of Three Phase 3, Randomized, Controlled Trials. [abstract]Arthritis Rheum201365Suppl 1031023203607
   PubMed Web of Science ®Google Scholar
• ZhangRMaratos-FlierEFlierJSReduced adiposity and high-fat diet-induced adipose inflammation in mice deficient for phosphodiesterase 4BEndocrinology200915073076308219359377
   PubMed Web of Science ®Google Scholar
• MeasePJGladmanDDKavanaughAChange in weight from baseline during the PALACE clinical trial program with apremilast, an oral phosphodiesterase 4 inhibitor: Pooled results from 3 phase 3, randomized, controlled trials. [abstract]Ann Rheum Dis201473Suppl 21055
   Web of Science ®Google Scholar
• LebwohlMGBachelezHBarkerJPatient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis SurveyJ Am Acad Dermatol201470587188124576585
   PubMed Web of Science ®Google Scholar
• SettyARCurhanGChoiHKObesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses’ Health Study IIArch Intern Med2007167151670167517698691
   PubMed Web of Science ®Google Scholar
• RichardGLangleyMDBoniESecukinumab in Plaque Psoriasis–Results of Two Phase 3 TrialsN Engl J Med2014371432633825007392
   PubMed Web of Science ®Google Scholar